Table 1.

Mean response and 95% confidence interval for each outcome measure at baseline and the 4-, 8-, and 12- week examinations, by treatment group.

	HBPP (n=54)		HBCVAT+ (n=53)		OBVAT (n=60)		OBPT (n=54)
	Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI
	CI Symptom Survey score
Baseline	27.8	25.8, 29.8	31.7	29.3, 34.1	30.2	27.7, 32.7	29.8	27.4, 32.2
Week 4
Unadjusted	25.5	23.0, 28.0	29.4	26.9, 31.9	25.4	22.9, 27.9	27.8	25.2, 30.4
Adjusted	26.9	25.2, 28.7	28.2	26.4, 30.0	25.2	23.6, 26.9	27.8	26.0, 29.5
Week 8
Unadjusted	24.9	22.2, 27.6	26.8	23.9, 29.7	21.2	18.6, 23.8	24.9	22.1, 27.7
Adjusted	26.5	24.2, 28.8	25.3	23.0, 27.6	20.9	18.7, 23.0	24.8	22.6, 27.1
Week 12
Unadjusted	21.3	18.0, 24.6	24.7	21.8, 27.6	15.1	12.6, 17.6	21.9	18.8, 25.0
Adjusted	22.9	20.4, 25.5	23.5	20.9, 26.0	15.0	12.6, 17.4	21.9	19.3, 24.4
	Near point of convergence break (cm)
Baseline	14.7	12.5, 16.9	14.4	12.4, 16.4	13.4	11.7, 15.1	14.4	12.3, 16.5
Week 4
Unadjusted	10.5	8.5, 12.5	10.0	8.0, 12.0	6.9	5.4, 8.4	12.1	10.1, 14.1
Adjusted	10.2	8.6, 11.9	10.0	8.4, 11.7	7.1	5.6, 8.7	12.0	10.4, 13.6
Week 8
Unadjusted	8.7	6.9, 10.5	8.4	6.8, 10.0	5.1	4.1, 6.1	11.0	9.1, 12.9
Adjusted	8.5	7.0, 9.9	8.3	6.9, 9.7	5.4	4.1, 6.7	10.9	9.5, 12.3
Week 12
Unadjusted	8.0	6.1, 9.9	6.8	5.2, 8.4	3.5	3.0, 4.0	10.3	8.4, 12.2
Adjusted	7.8	6.4, 9.2	6.8	5.4, 8.2	4.0	2.7, 5.3	10.3	8.9, 11.7
	Positive fusional vergence (Δ)
Baseline	11.3	10.2, 12.4	10.5	9.4, 11.6	11.0	9.9, 12.1	11.0	10.2, 11.8
Week 4
Unadjusted	15.4	13.5, 17.3	19.5	17.2, 21.8	22.1	19.2, 25.0	14.9	13.0, 16.8
Adjusted	15.2	12.9, 17.6	19.7	17.3, 22.0	22.3	20.1, 24.5	14.9	12.5, 17.2
Week 8
Unadjusted	17.2	15.1, 19.3	21.3	18.7, 23.9	26.9	23.7, 30.1	17.0	14.9, 19.1
Adjusted	17.0	14.5, 19.6	21.5	19.0, 24.0	26.9	24.5, 29.2	17.0	14.5, 19.6
Week 12
Unadjusted	19.1	16.8, 21.4	22.8	19.8, 25.8	30.7	27.5, 33.9	17.8	15.5, 20.1
Adjusted	18.9	16.2, 21.6	23.0	20.3, 25.7	30.5	28.0, 33.1	17.8	15.2, 20.5